MHRA Approves Deuruxolitinib for Severe Alopecia Areata

MHRA announced on 12 March 2026 that it approved deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults. MHRA also notes that the medicine was approved on 10 March 2026 to Sun Pharma UK Limited via the International Recognition Procedure.

The agency says that, as with any medicine, it will continue to keep the product’s safety and effectiveness under close review. That makes this a useful example of how regulators increasingly present approval and continued vigilance as part of one ongoing lifecycle, rather than separate phases.